DERMATOMYOSITIS

This study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…

This study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…

This early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…

This study planned to test deucravacitinib, a drug already approved for psoriasis, in adults with hard-to-treat dermatomyositis (DM) or juvenile dermatomyositis (JDM). Participants would have taken a pill twice daily for 24 weeks, with clinic visits every 4 weeks. However, the st…

This phase 3 trial tests an oral drug called brepocitinib in 241 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Participants receive either the drug or a placebo for 52 weeks to see if it improves symptoms. The study is active but no longer rec…

This study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and…

This study examines blood samples from 50 people with dermatomyositis, an autoimmune disease that raises the risk of cancer. Researchers are looking for new antibodies and immune molecules that might signal which patients are more likely to develop cancer. The goal is to improve …